Xinxiang Ruinuo Pharmaceutical Co., Ltd. was jointly funded by Shanghai Acebright Pharmaceuticals Group (Pusheng) Co., Ltd. and Xinxiang Ruicheng Technology Co., Ltd. in March 2017 as a manufacturing, researching and developing enterprise of new high-end pharmaceutical intermediates. Now, our company is located in the circular economy park of Industrial Cluster Zone of Xinxiang County, with a planning area of about 133,400 square meters and a current construction area of 33,350 square meters. Part of the technology and 49% of the investment is provided by Shanghai Acebright Pharmaceuticals Group. Headquartered in Shanghai, Shanghai Acebright Pharmaceuticals Group is a leading multinational company in the research and development of antiviral drugs worldwide. Plus precise management of Xinxiang Ruicheng Technology Co., Ltd., our company is focusing on the development of API industry chain projects to achieve the cycle development of economy. 

Our products are mainly used in nutrition and health care industry. As people's income levels increase, people's health care demand will grow rapidly; it is predicted that the entire health service industry will grow at a rate of 25% per year. We are committed to the research and development of APIs and key intermediates in two main lines (new anti-AIDS, anti-hepatitis B drugs and new B-vitamins), with a total investment of about CNY 1 billion. According to our plans, we are going to start the IPO in 2020 and enter the GEM in 2022, and then will become an important global research and development platform and production base of anti-HIV and vitamin supplements.